Orchid Pharma September profit before tax rises to Rs 36.76 crore

Orchid Pharma Limited reported unaudited standalone profit before tax of Rs 36.76 crore for the quarter ended September 30, 2026, up from Rs 6.91 crore a year earlier and Rs 11.94 crore in the preceding quarter. Net sales rose to Rs 341.27 crore, while the inventory-change line moved to negative Rs 38.95 crore.

What drove Orchid Pharma's September-quarter profit before tax?

Orchid Pharma's standalone profit before tax was Rs 36.76 crore in the September 30, 2026 quarter, compared with Rs 11.94 crore in the June 30, 2026 quarter and Rs 6.91 crore in the revised September 30, 2025 quarter. The profit before exceptional items and tax was also Rs 36.76 crore, as the standalone statement showed no exceptional item for the latest quarter.

Total standalone income rose to Rs 369.90 crore from Rs 314.22 crore in June 2026 and Rs 314.75 crore a year earlier. Net sales from operations accounted for Rs 341.27 crore, while other income was Rs 28.63 crore, against Rs 10.05 crore in the preceding quarter and Rs 16.29 crore in the prior-year quarter.

The change in inventories of raw materials, work-in-progress, stock-in-trade and finished goods was negative Rs 38.95 crore in September 2026. It was negative Rs 2.72 crore in June 2026 but a positive Rs 34.79 crore in September 2025, meaning this expense line reduced reported total expenses in the latest quarter rather than adding to them.

How did Orchid Pharma's sales and costs change?

Orchid Pharma's standalone net sales increased by Rs 37.10 crore from June 2026 and by Rs 42.81 crore from September 2025 to Rs 341.27 crore in the September 2026 quarter. Total income rose by Rs 55.68 crore sequentially and Rs 55.15 crore year on year, reflecting both higher sales and higher other income.

Cost of materials consumed rose to Rs 245.96 crore from Rs 206.42 crore in June 2026 and Rs 172.05 crore a year earlier. The increase in material consumption was partly offset in the expense statement by the negative Rs 38.95 crore inventory-change figure, which was Rs 36.23 crore more negative than the June-quarter amount.

Other expenses were Rs 77.04 crore, compared with Rs 57.75 crore in June 2026 and Rs 56.92 crore in September 2025. Employee benefit expenses rose to Rs 32.69 crore from Rs 26.76 crore sequentially, finance costs increased to Rs 3.66 crore from Rs 2.21 crore, and depreciation and amortisation was Rs 11.32 crore against Rs 10.93 crore.

Total expenses reached Rs 333.14 crore, an increase of Rs 30.86 crore from June 2026, compared with the Rs 55.68 crore increase in total income. Against September 2025, total expenses increased by Rs 25.30 crore while total income increased by Rs 55.15 crore, resulting in a Rs 29.85 crore rise in standalone profit before tax.

How did Orchid Pharma perform in the first half of 2026-27?

Orchid Pharma reported standalone profit before tax of Rs 48.70 crore for the six months ended September 30, 2026, compared with Rs 4.50 crore for the revised six months ended September 30, 2025. Half-year net sales rose to Rs 645.44 crore from Rs 561.64 crore in the comparable prior-year period.

Total standalone income for the six months was Rs 684.12 crore, against Rs 593.99 crore a year earlier, while total expenses increased to Rs 635.42 crore from Rs 589.48 crore. The inventory-change line was negative Rs 41.67 crore in the latest half year, compared with a positive Rs 13.69 crore in the September 2025 half year.

Standalone profit for the period was also Rs 48.70 crore because the displayed standalone tax expense lines show no amount for the six months ended September 2026. Basic and diluted earnings per share, or EPS, were Rs 8.13 for the half year, compared with Rs 0.75 in the revised prior-year period.

What do Orchid Pharma's consolidated results show?

Orchid Pharma reported consolidated profit before tax of Rs 26.84 crore for the September 2026 quarter, compared with Rs 2.65 crore in June 2026 and Rs 1.34 crore in the revised September 2025 quarter. Consolidated total income was Rs 359.02 crore, below standalone total income of Rs 369.90 crore for the same quarter.

Consolidated net sales were Rs 341.27 crore, the same as the standalone sales figure, while consolidated other income was Rs 17.76 crore versus standalone other income of Rs 28.63 crore. Consolidated total expenses were Rs 332.19 crore, compared with standalone expenses of Rs 333.14 crore.

Consolidated profit for the period was Rs 28.59 crore in September 2026, versus Rs 3.22 crore in June 2026 and a loss of Rs 0.90 crore a year earlier. For the six months ended September 30, 2026, consolidated profit before tax was Rs 29.49 crore, compared with a loss before tax of Rs 5.55 crore in the revised prior-year half year.

Conclusion

Orchid Pharma's September-quarter standalone result combined higher net sales of Rs 341.27 crore, other income of Rs 28.63 crore and a negative Rs 38.95 crore inventory-change line to produce profit before tax of Rs 36.76 crore. The half-year result followed the same direction, with profit before tax of Rs 48.70 crore against Rs 4.50 crore in the revised prior-year period.

The next comparison will show whether sales, other income and the inventory-change movement remain at September-quarter levels. The filing identifies the September 2025 comparatives and the March 31, 2026 figures as revised with reference to Note 6, but the supplied pages do not include the text explaining that revision.